Reimbursement for Solid Tumor Autologous Bone Marrow Transplantation Trials: A Strategy for Ensuring Continuation of a Promising Therapy
- 1 January 1991
- journal article
- research article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 9 (1) , 93-97
- https://doi.org/10.3109/07357909109032804
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Cost Effectiveness of Bone Marrow Transplantation in Acute Nonlymphocytic LeukemiaNew England Journal of Medicine, 1989
- High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer.Journal of Clinical Oncology, 1988
- The Crisis in Clinical Cancer ResearchNew England Journal of Medicine, 1988
- Comparison of Autologous and Allogeneic Bone Marrow Transplantation for Treatment of High-Risk Refractory Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 1987
- Autologous Bone Marrow Transplantation in Patients with Acute Nonlymphocytic Leukemia, Using ex Vivo Marrow Treatment with 4-HydroperoxycyclophosphamideNew England Journal of Medicine, 1986
- Questions and AnswersPublished by American Medical Association (AMA) ,1986
- Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer a phase I-II studyCancer, 1983
- High-dose cytosine arabinoside therapy for refractory leukemiaBlood, 1983
- Dose: A critical factor in cancer chemotherapyThe American Journal of Medicine, 1980
- High dose cytosine arabinoside (HDARAC) in refractory acute leukemiaCancer, 1979